Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 5
2006 3
2007 1
2008 7
2009 3
2010 5
2011 5
2012 7
2013 6
2014 4
2015 6
2016 4
2017 3
2018 4
2019 2
2020 1
2021 3
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
[Should we follow the guidelines?].
Gatell JM. Gatell JM. Enferm Infecc Microbiol Clin. 2009 Apr;27(4):197-8. doi: 10.1016/j.eimc.2009.01.002. Epub 2009 Mar 31. Enferm Infecc Microbiol Clin. 2009. PMID: 19339081 Spanish. No abstract available.
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018).
AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan:. AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan:. Enferm Infecc Microbiol Clin (Engl Ed). 2019 Mar;37(3):195-202. doi: 10.1016/j.eimc.2018.02.010. Epub 2018 Jun 18. Enferm Infecc Microbiol Clin (Engl Ed). 2019. PMID: 29759422 English, Spanish.
[Efficacy of atazanavir in simplification regimens].
Zamora L, Gatell JM. Zamora L, et al. Among authors: gatell jm. Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:14-21. doi: 10.1016/S0213-005X(08)76615-1. Enferm Infecc Microbiol Clin. 2008. PMID: 20116612 Review. Spanish.
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).
Expert Panel of GeSIDA and the National Aids Plan; Berenguer J, Polo R, Lozano F, López Aldeguer J, Antela A, Arribas JR, Asensi V, Blanco JR, Clotet B, Domingo P, Galindo MJ, Gatell JM, González-García J, Iribarren JA, Locutura J, López JC, Mallolas J, Martínez E, Miralles C, Miró JM, Moreno S, Palacios R, Pérez Elías MJ, Pineda JA, Podzamczer D, Portilla J, Pulido F, Ribera E, Riera M, Rubio R, Santos J, Sanz J, Tuset M, Vidal F, Rivero A. Expert Panel of GeSIDA and the National Aids Plan, et al. Among authors: gatell jm. Enferm Infecc Microbiol Clin. 2014 Aug-Sep;32(7):447-58. doi: 10.1016/j.eimc.2014.02.018. Epub 2014 Jun 28. Enferm Infecc Microbiol Clin. 2014. PMID: 24986715
Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015).
Expert Panel of GESIDA and the National AIDS Plan; Berenguer J, Polo R, Aldeguer JL, Lozano F, Aguirrebengoa K, Arribas JR, Blanco JR, Boix V, Casado JL, Clotet B, Crespo M, Domingo P, Estrada V, García F, Gatell JM, González-García J, Gutiérrez F, Iribarren JA, Knobel H, Llibre JM, Locutura J, López JC, Miró JM, Moreno S, Podzamczer D, Portilla J, Pulido F, Ribera E, Riera M, Rubio R, Santos J, Sanz-Moreno J, Sanz J, Téllez MJ, Tuset M, Rivero A. Expert Panel of GESIDA and the National AIDS Plan, et al. Among authors: gatell jm. Enferm Infecc Microbiol Clin. 2015 Oct;33(8):544-56. doi: 10.1016/j.eimc.2015.03.017. Epub 2015 May 26. Enferm Infecc Microbiol Clin. 2015. PMID: 26021186
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.
Saumoy M, Sánchez-Quesada JL, Assoumou L, Gatell JM, González-Cordón A, Guaraldi G, Domingo P, Giacomelli A, Connault J, Katlama C, Masiá M, Ordónez-Llanos J, Pozniak A, Martínez E, Podzamczer D. Saumoy M, et al. Among authors: gatell jm. J Antimicrob Chemother. 2022 Jun 29;77(7):1980-1988. doi: 10.1093/jac/dkac117. J Antimicrob Chemother. 2022. PMID: 35411401 Clinical Trial.
67 results